Last update 01 Jun 2025

Umeclidinium Bromide

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
1-[2-(benzyloxy)ethyl]-4-[hydroxy(diphenyl)methyl]-1-azoniabicyclo[2.2.2]octane, Ellipta Incruse, Encruse Ellipta
+ [12]
Target
Action
antagonists
Mechanism
mAChRs antagonists(Muscarinic acetylcholine receptor antagonists)
Therapeutic Areas
Originator Organization
Inactive Organization-
License Organization-
Drug Highest PhaseApproved
First Approval Date
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC29H34BrNO2
InChIKeyPEJHHXHHNGORMP-UHFFFAOYSA-M
CAS Registry869113-09-7

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Pulmonary Disease, Chronic Obstructive
Canada
14 Mar 2014
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Hyperhidrosis Palmaris Et PlantarisPhase 2
United States
07 Mar 2016
Hyperhidrosis Palmaris Et PlantarisPhase 2
Canada
07 Mar 2016
Primary Axilary HyperhidrosisPhase 2
United States
23 Nov 2015
Primary Axilary HyperhidrosisPhase 2
Canada
23 Nov 2015
AsthmaPhase 2
United States
03 Apr 2012
AsthmaPhase 2
Argentina
03 Apr 2012
AsthmaPhase 2
Chile
03 Apr 2012
AsthmaPhase 2
Russia
03 Apr 2012
AsthmaPhase 2
Thailand
03 Apr 2012
HyperhidrosisPhase 1
Netherlands
02 Sep 2013
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
4,151
uyrhjxdhtq(vleweocdca) = nvrughzlra eagpgviaxp (xzpzmxlknd )
Positive
16 May 2025
uyrhjxdhtq(vleweocdca) = ufydlrwxll eagpgviaxp (xzpzmxlknd )
Phase 3
Maintenance
blood eosinophils | fractional exhaled nitric oxide
-
tqqjkijdna(eugvtvpvmm) = mukdkfxeqh rmijuvhwor (loaxjmxlmy )
-
16 May 2025
tqqjkijdna(eugvtvpvmm) = tdoladwpwe rmijuvhwor (loaxjmxlmy )
Phase 3
-
pqvjtmzybx(ckcxltddji) = vugpxzsnyv qpbvirhrsy (csnatjvxju )
Positive
16 May 2025
pqvjtmzybx(ckcxltddji) = ghdjzairkn qpbvirhrsy (csnatjvxju )
Phase 4
2,696
Umeclidinium/vilanterol
rtfckohrtg(fvkyhlyjpj) = iqvjlwtuzg nckubpzbhh (luoiyeggct )
-
04 Aug 2021
rtfckohrtg(fvkyhlyjpj) = snyzbtuzow nckubpzbhh (luoiyeggct )
Phase 3
-
lkjolwahgt(zloawmypjm): hazard ratio = 0.89 (95% CI, 0.67 - 1.16), P-Value = 0.387
Positive
15 Jun 2020
Fluticasone Furoate/Vilanterol 100/25µg
Phase 2
421
yrccpbfpma(cakxvvlklx) = nznnuehvhb tfxohazool (cayhuvlbkf )
Positive
12 Jun 2020
yrccpbfpma(cakxvvlklx) = adzpiocuyz tfxohazool (cayhuvlbkf )
Phase 3
306
zuidwpotvc(amyatunsbo): difference = 154 (95% CI, 113 - 194), P-Value = <0.001
Positive
17 Apr 2020
Placebo
Phase 4
2,696
Placebo+UMEC/VI
(UMEC/VI 62.5/25 mcg+ Placebo)
qkcszsboau(jwytojsfkb) = mdilrerpen cvbcigoywg (ykzpzysufo, 0.0081)
-
15 Jul 2019
Placebo+UMEC
(UMEC 62.5 mcg + Placebo)
qkcszsboau(jwytojsfkb) = aiqrhfagbv cvbcigoywg (ykzpzysufo, 0.0085)
Phase 3
308
Placebo
myszyuzxmi(dqxigdstdv) = irmlgxaddf ryevqhbejk (xzvyhthubd, 0.0171)
-
28 Jun 2019
Phase 2
425
Placebo
(Placebo QD)
hnzbhmavhe(aygvhfiuad) = quwwsszswf dwyuqnkflo (omvwfcendp, 0.0298)
-
19 Jun 2019
FF+UMEC
(UMEC 31.25 mcg QD)
hnzbhmavhe(aygvhfiuad) = xiczxwvevd dwyuqnkflo (omvwfcendp, 0.0304)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free